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Reply to: Platelet function in patients with cirrhosis
The fact that platelets possess all the armamentarium to acti-
vate NADPH oxidase [4,5] is of relevance, not only for the hemo-
static system, but also for the extra-hemostatic effects potentially
played by platelets. The important issue raised by Drs. Lisman
and Porte is still to be adequately addressed, even if there is evi-
dence of a role of platelets in tumor metastasis, wound healing
and, overall, inﬂammation. Our data contribute to further expand
the knowledge on the pro-inﬂammatory role of platelets in as
much as NADPH oxidase is an enzyme of the innate immune sys-
tem with a crucial role for the bacterial killing via the production
of ROS [6]. In this regard, platelets may represent another
important component of the innate immune system, potentially
involved in the atherosclerotic process [7,8]. Thus, ROS
generation by NADPH oxidase is used by platelets to oxidize
LDL which are ultimately taken up by macrophages via scavenger
receptors [9]. Such an extra-hemostatic effect may implicate a
key role for platelets in the inﬂammatory process that initiates
atherosclerotic disease. The impact of this phenomenon in liver
cirrhosis remains, however, to be established.
How the complexity of these platelet functions relates to the
progression of liver cirrhosis, including bleeding and thrombosis,
is still a matter of debate and needs further investigation. For this
reason, we fully agree with Drs. Lisman and Porte that, currently,
the use of routine in vivo and ex vivo tests to explore global plate-
let function in cirrhosis is not useful for clinicians. However,
future research may identify new platelet biomarkers that will
help better understand the role of platelets in the bleeding
and thrombotic events that complicate the clinical course of
cirrhosis.
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Letters to the EditorTo the Editor:
We thank Drs. Lisman and Porte for their very interesting com-
ments concerning our review on the presence or absence of plate-
let dysfunction in liver cirrhosis. We agree that extrinsic and
intrinsic factors may contribute to maintain a normal primary
hemostasis in cirrhosis, despite potential defects due to thrombo-
cytopenia and anemia. Among the extrinsic factors, we agree that
the enhanced ratio vonWillebrand factor/ADAMTS 13 may have a
role. However, we have recently demonstrated the existence of a
novel intrinsic factor that could contribute to maintain a normal
hemostasis. We demonstrated that, upon stimulation, platelets
produce physiologic amounts of isoprostanes [1], which are
chemically stable eicosanoids derived from arachidonic acid
interaction with reactive oxidant species (ROS) [2]. In virtue of
these chemical characteristics, isoprostanes are useful in the late
phase of platelet activation, where they serve to propagate plate-
let aggregation via activation of the glycoprotein IIb/IIIa [1]. We
have recently discovered that the enzyme NADPH oxidase, one
of the most important cellular producers of ROS, has a key role
in the formation of platelet isoprostanes. Thus, in patients with
hereditary deﬁciency of the enzyme, platelet formation of iso-
prostanes is down-regulated. In particular, platelets from these
patients have impaired platelet activation, reinforcing the forma-
tion of isoprostanes as a relevant intracellular pathway for plate-
let function [1]. On the basis of these ﬁndings, we analyzed the
behavior of platelet isoprostanes and NADPH oxidase activation
in a population affected by cirrhosis. We found that platelet pro-
duction of isoprostanes was increased coincidentally with an up-
regulation of platelet NADPH oxidase, suggesting a cause-effect
relationship between them [3]. These changes were more evident
in patients with Child-Pugh’s classes B and C, indicating the
platelet over-expression of this pro-aggregating molecule typi-
cally occurs in patients with severe liver failure. This ﬁnding
was associated with systemic signs of platelet activation such
as enhanced soluble CD40L, corroborating the concept that in
liver cirrhosis platelets are more prone to be activated.994 Journal of Hepatology 2012 vol. 56 j 993–999
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The use of acoustic radiation force-based shear stiffness
in non-alcoholic fatty liver disease
To the Editor:
Palmeri and colleagues are to be congratulated on their study
assessing the utility of acoustic radiation force image impulse
(ARFI) to assess the severity of liver ﬁbrosis in patients with
non-alcoholic fatty liver disease (NAFLD) [1]. However, there
are several aspects from the study that need to be addressed.
Firstly, the number of unsuccessful stiffness reconstructions is
signiﬁcant at 37/172 (21.5%). This would represent a major draw-
back for any screening test used to gauge the severity of underly-
ing liver ﬁbrosis. In addition, the area under the curve (AUC) of
0.9 for the threshold given (P4.24 kPa) should be re-calculated
considering the frequency of the ﬁbrosis stages and the distribu-
tion of non-advanced and advanced liver ﬁbrosis (DANA) in the
study population using the method described by Poynard and
colleagues [2]. In common with all studies evaluating the accu-
racy of non-invasive markers using liver biopsy as the gold stan-
dard, the authors have omitted failed examinations from the ﬁnal
analysis. This is misleading as the accuracy and reproducibility of
ARFI is then conﬁned to successful readings and not the study
population as a whole. I think all such studies should have a sta-
tistical test similar to ‘‘an intention-to-treat’’ analysis in clinical
drug trials so that the accuracy of the study test is applied in
the context of an entire study population and not only those in
whom a result is achieved. Furthermore, as can be seen from
Fig. 2, the shear modulus across the liver ﬁbrosis stages is very
narrow from stage 0 to stage 4. Once again, this may make
interpretation of results difﬁcult, particularly for the lesser stages
i.e. stages F0–2, when clinicians may wish to identify early
disease to act early to prevent disease progression. This group
of patients is still likely to require a liver biopsy to differentiate
non-alcoholic steatohepatitis from NAFLD, negating the prime
beneﬁt of a non-invasive test. It would be useful to assess the
diagnostic accuracy of the test between different stages of ﬁbrosis
from F0 vs. F1–4 to F0123 vs. F4. One could then derive meaning-
ful cut-offs to help guide clinical decisions based on the sensitiv-
ity, speciﬁcity, negative and positive predictive values as well as
positive and negative likelihood ratios, of a respective test.
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